Erythropoietin prevents oxidative stress and lipid peroxidation process in human umbilical vein endothelial cells induced by tumor necrosis factor α;Erytropoetyna zapobiega stresowi oksydacyjnemu indukowanemu czynnikiem martwicy nowotworów α oraz procesowi peroksydacji lipidów w komórkach śródbłonka naczyń zylnych ludzkiej pȩpowiny

Polski Merkuriusz Lekarski

Volumn 21, Issue 126, 2006, Pages 534-539

  Szczepański, Marek ^a   Kamianowska, Monika ^a   Wnuczko, Krzysztof ^a   Skrzydlewska, Elzbieta ^a   Wołczyński, Sławomir ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Erythropoietin; Lipid peroxidation; Oxidative stress; TNF

Indexed keywords

ERYTHROPOIETIN; GLUTATHIONE; HYDROPEROXIDE DERIVATIVE; MALONALDEHYDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CELL LYSATE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIPID PEROXIDATION; OXIDATIVE STRESS; PROTEIN INDUCTION; UMBILICAL VEIN;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN, RECOMBINANT; GLUTATHIONE; HUMANS; LIPID PEROXIDATION; MALONDIALDEHYDE; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 33846359319     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Agnello D., Bigini P., Villa P. i wsp.: Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res., 2002, 952, 128-134.
2. Akisu M., Tuzun S., Arslanoglu S. i wsp.: Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzymes activities in preterm infants. Acta Med. Okayama. 2001, 55, 357-362.
3. Bany-Mohammed F.M., Slivka S., Hallman M.: Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits. Pediatr. Res., 1996, 40, 381-387.
4. Bartosz G.: Druga twarz tlenu. Wolne rodniki w przyrodzie. PWN. Warszawa. 2003.
5. Chattopadhyay A., Choudhury T.D., Bandyopadhyay D. i wsp.: Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem. Pharmacol., 2000, 59, 419-425.
6. Chong Z.Z., Kang J.Q., Maiese K.: Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J. Cereb. Blood Flow. Metab., 2002, 22, 503-514.
7. Comporti M.: Lipid peroxidation and biogenic aldehydes: from the identification of 4-hydroxynonenal to further achievements in biopathology. Free Radic. Res., 1998, 28, 623-635.
8. Corda S., Laplace C., Vicaut E. i wsp.: Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-α is mediated by ceramide. Am. J. Respir. Cell Mol. Biol., 2001, 24, 762-768.
9. Cristol J.P., Bosc J.Y., Badiou S. i wsp.: Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol. Dial. Transplant., 1997, 12, 2312-2317.
10. Cuzzocrea S., Mazzon E., Di Paola R. i wsp.: Erythropoietin reduces the development of experimental inflammatory bowel disease. J. Pharmacol. Exp Ther., 2004, 311, 1272-1280.
11. Digicaylioglu M., Lipton S.A.: Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature, 2001, 412, 641-647.
12. Eiselt J., Racek J., Opatrny K.: Oxidative stress: the effect of erythropoietin and the dialysis membrane. Int. J. Artif. Organs., 2000, 23, 33-40.
13. Fiordaliso F., Chimenti S., Staszewsky L. i wsp.: A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc. Nati. Acad. Sci. USA. 2005, 102, 2046-2051.
14. Gene S., Koroglu T.F., Genc K.: Erythropoietin as a novel neuroprotectant. Restor. Neurol. Neurosci., 2004, 22, 105-119.
15. Genc S., Koroglu T.F., Genc K.: Erythropoietin and the nervous system. Brain Res., 2004, 1000, 19-31.
16. Inal M., Kanbak G., Sen S. i wsp.: Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapy. Free Radic. Res., 1999, 31, 211-216.
17. 2. J. Clin. Invest., 1992, 89, 794-802.
18. Juul S.: Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr., 2002, 91, 36-42.
19. Kevil C.G., Pruitt H., Kavanagh T.J. i wsp.: Regulation of endothelial glutathione by ICAM-1: implications for inflammation. FASEB J., 2004, 18, 1321-1323.
20. Kumral A., Gonenc S., Acikgoz O. i wsp.: Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol. Neonate., 2005, 87, 15-18.
21. Maiese K., Li F., Chong Z.Z., Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol. Sci., 2004, 25, 577-583.
22. Maiese K., Li F., Chong Z.Z.: Wew avenues of exploration for erythropoietin. JAMA, 2005, 293, 90-95.
23. Marcho Z., White J.E., Higgins P.J. i wsp.: Tumor necrosis factor enhances endothelial cell susceptibility to oxygen toxicity: role of glutathione. Am. J. Respir. Cell Mol. Biol., 1991, 5, 556-562.
24. Marti H.M.: Review. Erythropoietin and the hypoxic brain. J. Exp. Biol., 2004, 207, 3233-3242.
25. Matthews N., Neale M.L., Jackson S.K. i wsp.: Tumour cell killing by tumour necrosis factor: inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism. Immunology, 1987, 62, 153-155.
26. Noyan T., Onem O., Sekeroglu M. i wsp.: Effects of erythropoietin and pentoxifylline on the oxidant and antioxidant systems in the experimental short bowel syndrome. Cell Biochem. Funct., 2003, 21, 49-54.
27. Ouyang J., Xia Z., Luo T. i wsp.: N-acetylcysteine dose-dependently reduces TNF-α cellular toxicity. Can. J. Anaesth., 2005, 52, 163.
28. Rutkowski B.: Erytropoetyna od odkrycia do zastosowań klinicznych. Makmed. Gdańsk. 2001, 16-26.
29. Scalera F.: Intracellular glutathione and lipid peroxide availability and the secretion of vasoactive substances by human umbilical vein endothelial cells after incubation with TNF-α. Eur. J. Clin. Invest., 2003, 33, 176-182.
30. Solaroglu I., Solaroglu A., Kaptanoglu E. i wsp.: Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv. Syst., 2003, 19, 19-22.
31. Sommerburg O., Grune T., Hampl H. i wsp.: Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol. Dial. Transplant., 1998, 13, 2583-2587.
32. Toborek M., Barger S.W., Mattson M.P. i wsp.: Role of glutathione redox cycle in TNF-α-mediated endothelial cell dysfunction. Atherosclerosis, 1995, 117, 179-188.
33. Uchida K.: 4-Hydroxy-2-nonenal: a product and mediator of oxidative Stress. Prog. Lipid Res., 2003, 42, 318-343.
34. Zhu D.Y., Li R., Liu G.Q. i wsp.: Tumor necrosis factor α enhances the cytotoxicity induced by nitric oxide in cultured cerebral endothelial cells. Life Sci., 2000, 66, 1325-1335.